Cargando…
Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study
AIM: To assess in real life the rate of hypoglycemia during Ramadan in patients with type 2 diabetes (T2DM) in France, according to their ongoing dual therapy of metformin-vildagliptin or metformin-sulfonylurea/glinide (IS). METHODS: Prospective, non-interventional study with 2 visits (within 8 week...
Autores principales: | Halimi, Serge, Levy, Marc, Huet, Dominique, Quéré, Stéphane, Dejager, Sylvie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889327/ https://www.ncbi.nlm.nih.gov/pubmed/23996548 http://dx.doi.org/10.1007/s13300-013-0038-7 |
Ejemplares similares
-
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
por: Schweizer, Anja, et al.
Publicado: (2013) -
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008) -
Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
por: Aziz, Kamran MA
Publicado: (2015) -
Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
por: Schweizer, Anja, et al.
Publicado: (2013) -
Verdi
por: Martin, George
Publicado: (1984)